Journal of Thoracic Oncology publication highlights the importance of very sensitive T790M detection in plasma for TKI treatment

 

Journal of Thoracic Oncology publication highlights the importance of very sensitive T790M detection in plasma for TKI treatment

The Journal of Thoracic Oncology recently published a study showing the added benefit of plasma genotyping for the selection of NSCLC-patients eligible for treatment with osimertinib. This publication (Buder et al. J Thorac Oncol 2018) presents the outcome of a study involving 119 patients and describes the treatment outcome on osimertinib for T790M-mutated patients screened with a very sensitive plasma test based on digital droplet PCR technology. The ddPCR plasma test provided a quantitative measurement of the number of T790M mutant copies in patient plasma and allowed the authors to evaluate therapeutic responses in function of the number of T790M copies present. Progression-free and overall survival tended to be prolonged in patients with low amounts of T790M, suggesting that quantification of mutant alleles might be clinically relevant.

The observed plasma T790M-positivity rate was 71%, and six additional patients with a T790M-mutation were identified by taking a tumour biopsy. However, it should be noted that a biopsy was feasible in only 42% of patients progressing on first-line TKI.

The authors concluded that plasma genotyping for T790M using ddPCR is clinically useful for the selection of patients for treatment with osimertinib after progression on EGFR-TKI therapy. Moreover, the clinical outcome of osimertinib treatment was similar in plasma T790M-positive patients compared to tissue T790M-positive patients, and plasma and tissue T790M genotyping are complementary techniques that identify additional patients.

Ask your AZ representative for a document summary and detailed discussion on this publication.

Journal of Thoracic Oncology
Journal of Thoracic Oncology

Rudy Hovelinck
Diagnostics Manager AstraZeneca

 

NS ID BE-1565-RD05/2018-LB Local code 509

Other Inside Diagnostic Articles

About the Author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

rudy.hovelinck@astrazeneca.com

M. +32 (0) 476 42 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.